- Regenerex Pharma, Inc. (RGPX) has entered into a **binding supply and development agreement** with **Holista Colltech Ltd.** for the exclusive worldwide rights to market Holista's proprietary ovine collagen products for wound care applications.  **[1357878_0001472375-25-000103_ixform8k.htm:1]** 
- Under the agreement, Holista will exclusively manufacture and supply its ovine collagen for Regenerex's use in the development, clinical testing, and global distribution of advanced wound care products, with an initial focus on the United States.  **[1357878_0001472375-25-000103_ixform8k.htm:1]** 
- Regenerex is committed to **minimum purchase commitments** of **USD50,000** in **2025**, scaling to **USD3 million** in **2026**, **USD6 million** in **2027**, and **USD9 million annually** from **2028 onwards**.  **[1357878_0001472375-25-000103_ixform8k.htm:1]** 
- Regenerex will also be responsible for conducting and funding clinical studies and regulatory approvals with the U.S. FDA and other relevant authorities.  **[1357878_0001472375-25-000103_ixform8k.htm:1]**

REGENEREX PHARMA (RGPX)